Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected

被引：0

作者：

Gallant, Joel ^{[1
]}

Brunetta, Jason ^{[2
]}

Crofoot, Gordon ^{[3
]}

Benson, Paul ^{[4
]}

Mills, Anthony ^{[5
]}

Brinson, Cynthia ^{[6
]}

Oka, Shinichi ^{[7
]}

Cheng, Andrew ^{[8
]}

Garner, Will ^{[8
]}

Fordyce, Marshall ^{[8
]}

Das, Moupali ^{[8
]}

McCallister, Scott ^{[8
]}

机构：

[1] Southwest CARE Ctr, 649 Harkle Rd,Ste E, Santa Fe, NM 87505 USA

[2] Univ Toronto, Family & Community Med, Toronto, ON, Canada

[3] Crofoot Res Ctr, Houston, TX USA

[4] Be Well Med Ctr, Berkley, MI USA

[5] Southern Calif Mens Med Grp, Los Angeles, CA USA

[6] Cent Texas Clin Res, Austin, TX USA

[7] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan

[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2016年 / 73卷 / 03期

关键词：

tenofovir alafenamide; TAF; elvitegravir; HIV; HBV; coinfection; bone; renal; TENOFOVIR DISOPROXIL FUMARATE; HIV-INFECTED PATIENTS; CHRONIC HEPATITIS-B; ANTIRETROVIRAL-NAIVE; ABACAVIR-LAMIVUDINE; EMTRICITABINE; PHARMACOKINETICS; EFAVIRENZ; DENSITY;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B. We report the results of an open-label, noncomparative switch study evaluating the efficacy and safety of E/C/F/TAF in HIV/hepatitis B virus (HBV)-coinfected adults. At 48 weeks, 91.7% of the 72 participants maintained or achieved virologic suppression (HIV-1 RNA <50 copies/mL; HBV DNA <29 IU/mL). Seroconversion occurred in 2.9% of hepatitis B surface antigen-positive participants and in 3.3% of HBV e antigen-positive participants; 40% of those with abnormal alanine aminotransferase normalized. E/C/F/TAF was associated with improved renal function and reduced bone turnover. These data support the use of E/C/F/TAF in treating HIV/HBV coinfection.

引用

页码：294 / 298

页数：5

共 50 条

[21] Safety and Efficacy of Coformulated Efavirenz/Emtricitabine/Tenofovir Single-Tablet Regimen in Treatment-Naive Patients Infected with HIV-1
Gallien, Sebastien
Flandre, Philippe
Nga Nguyen
De Castro, Nathalie
Molina, Jean-Michel
Delaugerre, Constance
JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (02) : 187 - 191
[22] Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States
Emond, Bruno
Rossi, Carmine
Cote-Sergent, Aurelie
Bookhart, Brahim
Anderson, David
Lefebvre, Patrick
Lafeuille, Marie-Helene
Donga, Prina
CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (02) : 287 - 298
[23] Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients
Ogbuagu, Onyema
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2016, 14 (12) : 1113 - 1126
[24] Network meta-analysis of darunavir/cobicistat/emtricitabine/tenofovir-alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide in treatment-naive patients with HIV-1 infection
Van Sanden, S.
Schweikert, B.
Moecklinghoff, C.
Tronczynski, K.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
[25] Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
Maggiolo, Franco
Rizzardini, Giuliano
Raffi, Francois
Pulido, Federico
Gracia Mateo-Garcia, Maria
Molina, Jean-Michel
Ong, Edmund
Shao, Yongwu
Piontkowsky, David
Das, Moupali
McNicholl, Ian
Haubrich, Richard
LANCET HIV, 2019, 6 (10): : E655 - E666
[26] Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single-tablet regimen in HIV-1-infected children (6 to <12 years)
Cotton, M.
Liberty, A.
Rodriguez, C. A.
Chokephaibulkit, K.
Kosalaraksa, P.
Hellstrom, E.
Natukunda, E.
Wong, P.
Majeed, S. R.
Quirk, E.
Graham, H.
Pikora, C.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 38 - 39
[27] Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects
Allavena, C.
Dailly, E.
Reliquet, V.
Bonnet, B.
Pineau, S.
Andre-Garnier, E.
Boutoille, D.
Bouquie, R.
Raveleau, A.
Bouchez, S.
Billaud, E.
Raffi, F.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (10) : 2804 - 2808
[28] Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
Emma D. Deeks
Drugs, 2018, 78 : 1013 - 1024
[29] Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
Deeks, Emma D.
DRUGS, 2018, 78 (10) : 1013 - 1024
[30] Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure
Inciarte, A.
Leal, L.
Gonzalez, E.
Leon, A.
Lucero, C.
Mallolas, J.
Torres, B.
Laguno, M.
Rojas, J.
Martinez-Rebollar, M.
Gonzalez-Cordon, A.
Cruceta, A.
Arnaiz, J. A.
Gatell, J. M.
Garcia, F.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (10) : 2857 - 2861

← 1 2 3 4 5 →